Table 2 Primary efficacy endpoints of quinine plus clindamycin and artemether-lumefantrine
| Â | Probability of cure | |||
|---|---|---|---|---|
Outcome | Quinine plus clindamycin | Artemether-lumefantrine | Risk difference (95% CI) | P-value |
Per protocol analysis | ||||
 PCR-uncorrected ACPR | 58/182 (31.9%) [25.1% to 38.7%] | 134/171 (78.4%) [72.2% to 84.6%] | − 46.5 [-36.1 to -56.9] |  < 0.0001 |
 PCR-corrected ACPR | 80/182 (44.0%) [36.8% to 51.2%] | 166/171 (97.1%) [94.6% to 99.6%] | − 53.1 [− 43.5 to − 62.7] |  < 0.0001 |
Intention-to-treat analysis | ||||
 PCR-uncorrected ACPR | 58/192 (30.2%) [23.7% to 36.7%] | 134/192 (69.8%) [63.3% to 76.3%] | − 39.6 [− 29.6 to − 49.6] |  < 0.0001 |
 PCR-corrected ACPR | 80/192 (41.7%) [34.7% to 48.7%] | 166/192 (86.5%) [81.7% to 91.3%] | − 44.8 [− 35.2 to − 54.4] |  < 0.0001 |